Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

ation about IMBRUVICA, including the full prescribing information, please visit www.IMBRUVICA.com. IMBRUVICA is a first in class, oral therapy and is a new agent that inhibits a protein called Bruton's tyrosine kinase (BTK). BTK is a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to grow and divide uncontrollably. It is one of the first medicines to receive FDA approval via the new Breakthrough Therapy Designation pathway, enabling Pharmacyclics to rapidly bring this medicine to patients in need.

To date, nine Phase III trials have been initiated with IMBRUVICA and a total of 38 trials are currently registered on www.clinicaltrials.gov. Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize IMBRUVICA.

About Pharmacyclics
Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and several preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it mov
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... , Aug. 21, 2014 Nektar ... International Inc. today announced positive results from its ... an investigational, extended half-life recombinant factor VIII (rFVIII) ... Factor (Recombinant)], which met its primary endpoint in ... arm compared to the on-demand arm. ...
(Date:8/21/2014)... Canadian Epilepsy Alliance (CEA) is thrilled to announce the launch ... the most common neurological disorder in Canada ... tells a fictional story based on the experiences of 14-year-old ... "Despite the fact that epilepsy affects 1 ... lack of awareness out there," says Gail Dempsey , ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
(Date:8/22/2014)... LA The LSU Health New Orleans School ... Nursing Traineeship grant to increase access to advanced ... and under-represented groups, as well as veterans. The ... Department of Health and Human Services awarded the ... as the grant,s project director., The Advanced Education ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... oncogenic somatic mutation at amino acid 918 in the ... small cell lung cancer (SCLC) tumors and enforced expression ... intracellular signaling and cell growth. , SCLC is a ... all lung cancers and is strongly associated with tobacco ... extensively examined for genomic alterations and targeted therapies are ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... 28 WellSpring Pharmaceutical,Corporation, a growing North American-based ... named Chief Operating Officer.,Formerly, Ms. Shusko held the ... in early 2000. In her new role as ... her areas of oversight,to operations with an initial ...
... NQF-endorsed measures can improve quality of care for ... the,importance of quality healthcare for mothers and newborns ... measure and thereby,improve care received by mothers and ... discharge. Consensus standards improve quality,of care by standardizing ...
... who received blood that was 29 days or older faced ... Hospital patients who receive a transfusion of stored blood that ... developing one or more serious infections compared to those who ... pointed out that current U.S. regulations set the upper limit ...
... Device Designed to Minimize Discomfort and Pain Following ... a world-leading,manufacturer of ostomy and wound care products, ... a new post-operative ostomy,device. The product offers clinicians ... manage abdominal pain in the days and weeks ...
... Today, PARI Respiratory,Equipment presented a comparative study ... in-vitro performance and delivery,efficiency of budesonide inhalation ... study show that the LC Sprint,Reusable Nebulizer ... average,of 4.9 minutes, and had the highest ...
... of Portland,Oregon is pleased to announce its partnership ... a new company, Wellsource Health Solutions.,This joint venture ... provide,full-service solutions that meet the specific needs of ... Customers and their,participants will benefit from a new ...
Cached Medicine News:Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 2Health News:National Quality Forum Endorses National Consensus Standards for Perinatal Care 3Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 2Health News:ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor 3Health News:PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 2Health News:Wellsource Partners With Health Solutions Ltd. to Form Best-in-Class Health and Wellness Solutions for Its Clients. 3
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Ultraview 1700 Central Monitor...
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
Medicine Products: